Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

Overview

Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patient with opioid dependence. Patients who have completed 24 weeks of treatment in the Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients with Opioid Dependence, will be re-treated with Probuphine over an additional 24 weeks.

Full Title of Study: “An Open-Label, Multi-Center Extension Study Of Probuphine in Patients With Opioid Dependence”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2009

Interventions

  • Drug: Probuphine (buprenorphine implant)
    • Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants, 6-month duration).

Arms, Groups and Cohorts

  • Experimental: Probuphine
    • buprenorphine implant

Clinical Trial Outcome Measures

Primary Measures

  • Number of subjects with adverse events as a measure of safety
    • Time Frame: approx. 26 weeks
    • Adverse events that occurred after the signing of the informed consent until 14 days after study drug treatment has been discontinued, or AEs designated as possibly-related to study drug and all Serious AEs until resolution or stabilization, were followed.

Secondary Measures

  • Buprenorphine concentration in plasma
    • Time Frame: 24 weeks
  • Percent of urine samples that are negative for illicit opioids
    • Time Frame: 24 weeks
  • Percent of subjects retained as a measure of efficacy
    • Time Frame: 24 weeks
  • Percent of subjects reporting illicit drug use as a measure of efficacy
    • Time Frame: 24 weeks
  • Average daily dose of supplemental sublingual buprenorphine as a measure of efficacy
    • Time Frame: 24 weeks
  • Mean total score on SOWS as a measure of efficacy
    • Time Frame: 24 weeks
  • Mean total score on COWS as a measure of efficacy
    • Time Frame: 24 weeks
  • Mean subjective opioid cravings scores as a measure of efficacy
    • Time Frame: 24 weeks
  • Mean composite score Drug Problems area of Addiction Severity Index
    • Time Frame: Baseline and End of Treatment
  • Patient-rated Opioid use and Problems Responder Analysis as a measure of efficacy
    • Time Frame: 24 weeks
  • Physician-rated severity of opioid use and symptoms Responder Analysis as a measure of efficacy
    • Time Frame: 24 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Voluntarily provide written informed consent prior to conduct of any study-related procedures – Completed 24 weeks of treatment in PRO-805 – Deemed appropriate for entry into this extension study by the Investigator – Females of childbearing potential and fertile males must use a reliable means of contraception Exclusion Criteria:

  • Presence of aspartate aminotransferase (AST) levels ≥ 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels ≥ 3 X upper limit of normal and/or total bilirubin ≥ 1.5 X upper limit of normal and/or creatinine ≥ 1.5 X upper limit of normal – Current diagnosis of chronic pain requiring opioids for treatment – Pregnant or lactating females – Current use of agents metabolized through cytochrome P450 3A4 (CYP 3A4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir) – Current anti-coagulant therapy (such as warfarin) or an INR > 1.2 – Current use of benzodiazepines other than physician prescribed use – Significant medical or psychiatric symptoms, cognitive impairment, or other factors which in the opinion of the Investigator, would preclude compliance with the protocol, patient safety, adequate cooperation in the study, or obtaining informed consent – Concurrent medical conditions (such as severe respiratory insufficiency) that may prevent the patient from safely participating in study; and/or any pending legal action that could prohibit participation and/or compliance in study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Titan Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.